Program
SHR-4610
A development code. Also written as “SHR-4610 Injection” and “SHR-8068 ; SHR-4610”.
Its studies are mostly in Carcinoma, Renal Cell, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 22 open or running | phase 2since Nov 13, 2025 | Nov 13, 2025 | Dec 2030phase 2 · NCT07239596 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-4610
, phase 1, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2025First studies: 2 phase 2 studiesFirst studyNCT07231211, NCT07239596
Ahead
- Dec 2030Primary completion: phase 2 study in Advanced Renal Cell CarcinomaNCT07239596
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07239596Advanced Renal Cell Carcinoma · China | 2 | Recruiting | Dec 2030 | 92 |
| NCT07231211Solid Tumors · China | 2 | Recruiting | Oct 2026 | 258 |
How it is read
Names in the registry
- “SHR-4610 Injection”, 1 entry
- “SHR-8068 ; SHR-4610”, 1 entry
Codes read as this program: SHR4610.
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.